The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Open accessAbstract
Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries. Proliferative DR (PDR) represents the last stage of this extremely complex retinal disease, characterized by the development of neovascularization induced by the abnormal production and release of vascular endothelial growth factor (VEGF). The term VEGF includes different isoforms; VEGF-A represents one of the most important pathogenic factors of DR. Anti-VEGF intravitreal therapies radically changed the outcome of DR, due to combined anti-angiogenic and anti-edematous activities. Nowadays, several anti-VEGF molecules exist, characterized by different pharmacological features and duration. With respect to PDR, although anti-VEGF treatments represented a fundamental step forward in the management of this dramatic complication, a big debate is present in the literature regarding the role of anti-VEGF as substitute of panretinal photocoagulation or if these two approaches may be used in combination. In the present review, we provided an update on VEGF isoforms and their role in DR pathogenesis, on current anti-VEGF molecules and emerging new drugs, and on the current management strategies of PDR. There is an overall agreement regarding the relative advantage provided by anti-VEGF, especially looking at the management of PDR patients requiring vitrectomy, with respect to laser. Based on the current data, laser approaches might be avoided when a perfectly planned anti-VEGF therapeutic strategy can be adopted. Conversely, laser treatment may have a role for those patients unable to guarantee enough compliance to anti-VEGF injections.Key messagesVEGF increased production, stimulated by retinal hypoperfusion and ischaemia, is a major pathogenic factor of neovascular complication onset in diabetic retinopathy and of DR stages progression.Nowadays, several anti-VEGF molecules are available in clinical practice and other molecules are currently under investigation. Each anti-VEGF molecule is characterized by different targets and may interact with multiple biochemical pathways within the eye.All the data agreed in considering anti-VEGF molecules as a first line choice for the management of diabetic retinopathy. Laser treatments may have a role in selected advanced cases and for those patients unable to guarantee enough compliance to intravitreal treatments schemes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 2×
“receptor [15], platelet derived growth factor (PDGF) [37] and advanced glycation end-products [38].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 3×
“This is obtained from the fusion of the first three Ig domains of VEGFR-1 and the Fc region of human IgG1 [96].”
BackgroundAntonetti, D. A., Klein, R., & Gardner, T. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1005073 · Cited by 1,659
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
Robinson, C. J., & Stringer, S. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.853 · Cited by 944
Insight into the physiological functions of PDGF through genetic studies in mice
Betsholtz, C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.005 · Cited by 437 · cited 2×
“Furthermore, the dysregulation of many other mediators is involved in the promotion of VEGF release, including erythropoietin (EPO) [36], angiopoietins 1 and 2 (Ang-1 and Ang-2), Tie2 receptor [15], platelet derived growth factor (PDGF) [37] and advanced glycation end-products [38].”
BackgroundMaguire, M. G., Liu, D., Glassman, A. R., Jampol, L. M., Johnson, C. A., Baker, C. W., Bressler, N. M., Gardner, T. W., Pieramici, D., Stockdale, C. R., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5939 · Cited by 61
Cited by
Xu, M., Fan, R., Fan, X., Shao, Y., & Li, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s383101 · Cited by 111
Xu, J.-F., Wang, Y.-P., & Liu, X.-H. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.06.019 · Cited by 12
Insights into the molecular underpinning of type 2 diabetes complications
Singh, A., Bocher, O., & Zeggini, E. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddae203 · Cited by 10
Metadata
- Authors
- Arrigo, A., Aragona, E., & Bandello, F.
- Venue
- Annals of Medicine
- Publisher
- Informa UK Limited
- Published
- 2022-04-22
- Volume
- 54
- Issue
- 1
- Pages
- 1089-1111
- ISSN
- 0785-3890 (ISSN-L)
- 1365-2060
- OpenAlex
- W4224229807
- Cited by
- 192
- References
- 7
- FWCI
- 27.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. https://app.cochat.ai/papers/10.1080/07853890.2022.2064541
- The paper
- Arrigo, A., Aragona, E., & Bandello, F. (2022). VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Annals of Medicine. https://doi.org/10.1080/07853890.2022.2064541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.